Investor Presentaiton

Etrasimod Provides Pipeline Diversification and Significant Potential Revenue Contribution in Critical 2025-2030 Timeframe ◉ Expands Pfizer's current offering in IBD ■ ■ Best-in-Class efficacy potential in Ulcerative Colitis, and robust risk-benefit profile Potential Lifecycle expansion into Crohn's Disease and EOE expands footprint further in Gastroenterology Complementary MOA to current portfolio; potentially enabling treatment of a broader sub-set of UC patients Enhances portfolio in critical years 2021 2022 2023 2024 2025 2026 2027 2028 2029+ XELJANZ [tofacitinib] LOE CIBINQO (abrocitinib) tablets) Ritlecitinib AA Ritlecitinib Vitiligo TL1A and Ritlecitinib Emerging GI Pipeline for UC &CD I&I Portfolio XELJANZ [tofacitinib] Etrasimod Pfizer UC AD CD EOE Dates indicate anticipated future approval timing; all dates are subject to change and subject to clinical and regulatory success EOE: Eosinophilic Esophagitis, IBD: Irritable Bowel Disease, MOA: Mechanism of Action, UC: Ulcerative Colitis, AD: Atopic Dermatitis, AA: Alopecia Areata, LOE: Loss of Exclusivity, CD: Crohn's Disease AA 11

View entire presentation